Home » Stocks » VVOS

Vivos Therapeutics, Inc. (VVOS)

Stock Price: $8.15 USD -0.22 (-2.63%)
Updated Apr 19, 2021 10:27 AM EDT - Market open
Market Cap 104.88M
Revenue (ttm) 13.07M
Net Income (ttm) -17.99M
Shares Out 12.87M
EPS (ttm) -1.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $8.15
Previous Close $8.37
Change ($) -0.22
Change (%) -2.63%
Day's Open 8.36
Day's Range 8.06 - 8.60
Day's Volume 14,409
52-Week Range 5.64 - 14.41

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

HIGHLANDS RANCH, Colo., April 14, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diag...

5 days ago - GlobeNewsWire

Vivos management to present at 9:00 am EDT on April 14, 2021 Vivos management to present at 9:00 am EDT on April 14, 2021

1 week ago - GlobeNewsWire

Three stocks to have on your radar in the healthcare space.

Other stocks mentioned: INSP, RMD
1 week ago - The Motley Fool

Vivos management to present at 1:30 pm Eastern Time on March 23, 2021

1 month ago - GlobeNewsWire

Physicians and Dentists Collaborate to Offer Vivos System Treatment to Patients Suffering from Sleep Apnea Physicians and Dentists Collaborate to Offer Vivos System Treatment to Patients Suffering from ...

1 month ago - GlobeNewsWire

If Approved for Clearance, Vivos' Updated Device Will Treat Mild to Moderate Sleep Apnea and Expand Insurance Reimbursement to include Medicare Coverage If Approved for Clearance, Vivos' Updated Device ...

2 months ago - GlobeNewsWire

Internationally Recognized Medical and Dental Industry Veterans Will Work Closely with Vivos Management to Drive Further Commercial Success Internationally Recognized Medical and Dental Industry Veteran...

2 months ago - GlobeNewsWire

Cyclo Therapeutics (NASDAQ: CYTH) shares are trading higher Tuesday after the company announced "positive" efficacy data from an extension protocol with Trappsol Cyclo in patients with Niemann-Pick Dise...

Other stocks mentioned: MRKR, THC, CYTH
3 months ago - Benzinga

HIGHLANDS RANCH, Colo., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos”) today announced the closing of its initial public offering of 4,025,000 shares of its common stock. The offer...

4 months ago - GlobeNewsWire

HIGHLANDS RANCH, Colo., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“ Vivos ”), a medical technology company that offers novel and proprietary alternatives for treating mild-to-moderate ...

4 months ago - GlobeNewsWire

Vivos Therapeutics, Inc., a medical technology company that offers novel and proprietary alternatives for treating mild-to-moderate obstructive sleep apnea, today announced that is has filed a registrat...

6 months ago - GlobeNewswire

Vivos Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ stock exchange.

6 months ago - SEC

About VVOS

Vivos Therapeutics is a revenue stage medical technology company focused on the development and commercialization of a highly differentiated technology offering a clinically effective non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). We offer novel and proprietary alternatives for treating mild-to-moderate OSA as well as certain craniofacial and anatomical anomalies known to be associated with mild-to-moderate OSA. W... [Read more...]

Industry
Medical Devices
IPO Date
Dec 11, 2020
CEO
R. Kirk Huntsman
Employees
93
Stock Exchange
NASDAQ
Ticker Symbol
VVOS
Full Company Profile

Financial Performance

In 2020, VVOS's revenue was $13.07 million, an increase of 14.68% compared to the previous year's $11.39 million. Losses were -$12.06 million, 12.1% more than in 2019.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for VVOS stock is "Buy." The 12-month stock price forecast is 12.00, which is an increase of 47.24% from the latest price.

Price Target
$12.00
(47.24% upside)
Analyst Consensus: Buy